View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 23, 2021

Covaxin Phase III data shows jab to be 77.8% effective ahead of WHO meeting

India’s first indigenous vaccine comes out as 77.8% effective in Phase III trials, just in time for a WHO meeting.

By Kezia Parkins

Long-awaited data of Bharat Biotech’s Covid-19 vaccine Covaxin has demonstrated a 77.8% efficacy in Phase III trials.

The Subject Expert Committee (SEC) met on Tuesday to review the data but has not yet approved it.

The SEC will now send the data to the Drugs Controller General of India (DCGI) for review.

According to the data submitted, Covaxin demonstrated an efficacy of 77.8% during the trial, which was conducted on 25,800 subjects.

The data comes just in time for Bharat Biotech’s 23 June meeting with the World Health Organization (WHO), where it is expected to submit its proposal for an Emergency Use Listing (EUL) for Covaxin.

On 18 June, the WHO accepted the Hyderabad-based company’s Expression of Interest for Covaxin to get EUL.

Last month, the firm stated that it expects to receive EUL approval for Covaxin between July and September.

EUL is the procedure to streamline the process so that new or unlicensed products can be used during public health emergencies like the Covid-19 pandemic.

The EUL would make it more straightforward for Covaxin – India’s first homegrown vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – to get approvals in other countries.

The sharing of the Phase III data comes after months of controversy following the vaccine’s restricted-use approval from India’s leading drug regulator, the Central Drugs Standard Control Organization (CDSCO) in January when no such data was available.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy